Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
SAGE Therapeutics
SAGE Therapeutics is developing medicines to treat rare and orphan diseases of the central nervous system.
Sector
Subsector
Location
total rounds
total raised
Cerebral Therapeutics
Cerebral Therapeutics develops combination therapies for refractory epilepsy and neurological diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Denali Therapeutics
Denali Therapeutics develops therapies for neurodegenerative diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Travere Therapeutics
Travere Therapeutics develops life-changing therapies for rare diseases.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 19.03.2024. Their latest investor Abrdn. Their latest round Series B
F-Prime Capital
F-Prime Capital is a venture capital firm that invests in technology, healthcare and life sciences sectors in the United States and Europe.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Norwest Venture Partners
Norwest is a global venture capital and growth equity investment firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Nan Fung Life Sciences
Nan Fung Life Sciences is a global life sciences investment platform backed by the Nan Fung Group.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Nan Fung Life Sciences
Nan Fung Life Sciences is a global life sciences investment platform backed by the Nan Fung Group.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors11
Number of lead investors
Number of investors
Abrdn
Abrdn is a UK-based company that offers a full range of capabilities to empower clients in planning, saving and investing for their futures.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Longwood Fund
Longwood Fund is a venture capital firm that invests in healthcare and life science companies, focusing on biotechnology and therapeutics.
Sector
Subsector
Location
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Jasper Bos
Jasper Bos, PhD is Director with Merck Serono Ventures, the corporate venture capital fund of Merck Serono SA, which invests in early stage and start-up biotech and pharmaceutical companies. Prior to joining Merck Serono SA, Jasper was instrumental in the founding of IFHA, a private equity fund backed by large Dutch and international institutional investors. He was instrumental in the structuring and capital raise of IFHA and negotiated and managed private equity investments in emerging economies in the healthcare and insurance sectors. Before IFHA, Jasper worked as health economics and strategy manager at the Netherlands Vaccine Institute. Currently, he is a Member of the Board of Directors of Prexton Therapeutics SA, EpiTherapeutics AS, Galecto Biotech, Neviah Genomics and an Observer to the Board of Vaximm AG. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands and has published more than 30 articles on health economics and vaccines.
current job
Acquisitions1
Neurocycle Therapeutics acquired by Engrail Therapeutics
acquirer
date
type
Neurocycle Therapeutics
Neurocycle Therapeutics is a biopharmaceutical company specializing in sub-type selective GABA-A modulation.
Sector
Subsector
Location
total rounds
total raised
People
Founders2
Stephen Cunningham
Dr. Stephen Cunningham is a 25 year pharmaceutical veteran who has led teams that delivered on the development, regulatory approvals and launch of numerous significant products to improve patient health. He has global experience leading cross-functional teams from Phase 1 through life cycle management in the areas of Neuroscience, Cardiovascular, Metabolism, Respiratory, Immunology, Oncology, Women’s Health, Transplant and Clinical Pharmacology. During his career, Stephen lead and developed diverse cross-functional teams in Europe, Japan, Asia, Canada and the United States and has broad and deep experience in setting strategic direction, delivering projects, restructuring organizations and implementing transformational organization change. Stephen started his career at ICI Pharmaceuticals, holding global positions of increasing responsibility at ICI, Zeneca then Novartis. After joining Novartis in 2000 as Head of Medical Affairs in the US, Stephen quickly assumed the role of Chief Scientific Officer and Head of US Clinical Development, Medical Affairs and Evidence-Based Medicine in 2001. While at Novartis he built a world-class Novartis US Clinical Development and Medical Affairs organization supporting drug development, launch and life cycle management of products worldwide. Since 2014, Stephen has worked with venture capital, as a strategic consultant and as an independent board director.
current job
organization founded
Stephen Cunningham
Vikram Sudarsan
Vikram Sudarsan is Strategy Head of Cipla New Ventures at Cipla USA since October 2013. Vikram is a versatile biotech pharma professional with deep expertise in the scientific and commercial aspects of drug development. Prior to joining Cipla, Vikram helped start IMS's new Transaction Advisory Practice – IMS Health Capital, Inc. as an Engagement Manager in Partnership. Prior to that Vikram helped establish and grow the Asset Valuation practice at PriceSpective, LLC before its sale to ICON Plc. At IMS and PriceSpective he built a differentiated risk-sharing based licensing, mergers & acquisitions business. Vikram led global teams to develop a deep understanding of assets value and potential before advising clients on transactions. Vikram has led due diligence projects for several of the top twenty pharma companies on the buy-side and strategy development projects for numerous small biotech clients on the sell-side. Vikram is an INLAKS scholar. Vikram has a Ph.D. in Genetics from University of Sheffield, UK and carried out his doctoral research at the University of Cambridge. Vikram has a Post Doctorate in Neurobiology from Stanford University Howard Hughes Medical Institute. Vikram has an M.Sc. degree in Biochemistry from MS University Baroda.
current job
Vikram Sudarsan
Employee Profiles2
Stephen Cunningham
Co-Founder ,Executive VP & Chief Development Officer
Activity
Recent News4
The graph reveals the ratio (%) of positive news articles in a chosen time range